Author Title Type [ Year(Asc)]
Filters: Author is Blazar, Bruce R  [Clear All Filters]
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Saha A, Hyzy S, Lamothe TLaforest, Hammond KJ, Clark NM, Lanieri L, Bhattarai PRaj, Palchaudhuri R, Gillard GO, Proctor J, et al. CD45-targeted antibody-drug-conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation. Blood. 2022.
Buxbaum NProkopenko, Socié G, Hill GR, MacDonald KPa, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, et al. Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Stefanski HE, Xing Y, Nicholls J, Jonart L, Goren E, Taylor PA, Mills AA, Riddle M, McGrath J, Tolar J, et al. P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss. PLoS One. 2022;17(1):e0261770.
Ramos TLopes, Bolivar-Wagers S, Jin S, Thangavelu G, Simonetta F, Lin P-Y, Hirai T, Saha A, Koehn BH, Su LL, et al. Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo. Blood. 2022.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau T-O, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, et al. Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022.